OBJECTIVE: The basal activity of p38 MAPK has recently been shown to impair myocardial contractility. This kinase is activated by ischemia and short-term hibernation. We hypothesized that p38 MAPK activation may contribute to the contractile deficit that characterizes low-flow ischemia. METHODS: In Langendorff-perfused isolated C57BL/6 mouse hearts, perfusion pressure was reduced from 85 to 15 or 30 mm Hg for 120 min to induce ischemic left ventricular dysfunction. The effect of the p38 MAPK inhibitor SB203580 (1 microM/l) on contractile function and p38 MAPK activation was assessed. RESULTS: Reduction in perfusion pressure to 15 or 30 mm Hg was accompanied by stable reductions in coronary flow (83+/-2% and 66+/-2%, respectively) and developed pressure (84+/-2% and 61+/-3%), with minimal infarction (15.6+/-0.69% and 10.6+/-0.98% of LV myocardium, respectively), but marked activation of p38 MAPK (reflected in pHSP27 1092+/-326% basal and 996+/-301% basal, respectively). The p38 MAPK inhibitor SB203580, present during the last 60 min of reduced pressure perfusion, prevented p38 MAPK activation (pHSP27 281+/-92% basal, p=0.01 and 186+/-72% basal, p=0.01) but, despite the presence of a contractile reserve, had no effect on developed pressure. Similarly, early treatment with SB203580 started 5 min after the onset of reduced flow also failed to attenuate contractile dysfunction. CONCLUSION: The p38 MAPK activation that accompanies short-term hibernation does not appear to contribute to the contractile deficit.
OBJECTIVE: The basal activity of p38 MAPK has recently been shown to impair myocardial contractility. This kinase is activated by ischemia and short-term hibernation. We hypothesized that p38 MAPK activation may contribute to the contractile deficit that characterizes low-flow ischemia. METHODS: In Langendorff-perfused isolated C57BL/6 mouse hearts, perfusion pressure was reduced from 85 to 15 or 30 mm Hg for 120 min to induce ischemic left ventricular dysfunction. The effect of the p38 MAPK inhibitor SB203580 (1 microM/l) on contractile function and p38 MAPK activation was assessed. RESULTS: Reduction in perfusion pressure to 15 or 30 mm Hg was accompanied by stable reductions in coronary flow (83+/-2% and 66+/-2%, respectively) and developed pressure (84+/-2% and 61+/-3%), with minimal infarction (15.6+/-0.69% and 10.6+/-0.98% of LV myocardium, respectively), but marked activation of p38 MAPK (reflected in pHSP27 1092+/-326% basal and 996+/-301% basal, respectively). The p38 MAPK inhibitor SB203580, present during the last 60 min of reduced pressure perfusion, prevented p38 MAPK activation (pHSP27 281+/-92% basal, p=0.01 and 186+/-72% basal, p=0.01) but, despite the presence of a contractile reserve, had no effect on developed pressure. Similarly, early treatment with SB203580 started 5 min after the onset of reduced flow also failed to attenuate contractile dysfunction. CONCLUSION: The p38 MAPK activation that accompanies short-term hibernation does not appear to contribute to the contractile deficit.
Authors: S Frantz; T Behr; K Hu; D Fraccarollo; J Strotmann; E Goldberg; G Ertl; C E Angermann; J Bauersachs Journal: Br J Pharmacol Date: 2006-12-18 Impact factor: 8.739
Authors: Ruma Pengal; Adam J Guess; Shipra Agrawal; Joshua Manley; Richard F Ransom; Robert J Mourey; Rainer Benndorf; William E Smoyer Journal: Am J Physiol Renal Physiol Date: 2011-05-25
Authors: D Westermann; S Rutschow; S Van Linthout; A Linderer; C Bücker-Gärtner; M Sobirey; A Riad; M Pauschinger; H-P Schultheiss; C Tschöpe Journal: Diabetologia Date: 2006-08-26 Impact factor: 10.122
Authors: Richard T Clements; Jun Feng; Brenda Cordeiro; Cesario Bianchi; Frank W Sellke Journal: Am J Physiol Heart Circ Physiol Date: 2011-02-25 Impact factor: 4.733
Authors: Sebastien Jacquet; Yasuhiro Nishino; Sarawut Kumphune; Pierre Sicard; James E Clark; Koichi S Kobayashi; Richard A Flavell; Jan Eickhoff; Matt Cotten; Michael S Marber Journal: J Biol Chem Date: 2008-02-29 Impact factor: 5.157